Managing homozygous familial hypercholesterolaemia from cradle to grave

Atherosclerosis Supplements

Volumn 18, Issue , 2015, Pages 16-20

  Thompson, Gilbert R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Compound heterozygote; Homozygote; Hypercholesterolaemia; Lipoprotein apheresis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; METOPROLOL; RECEPTOR; SIMVASTATIN; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACHILLES TENDON; ADULT; ANGINA PECTORIS; AORTA ROOT; AORTA STENOSIS; APHERESIS; ARM; ARTERIOVENOUS SHUNT; ARTICLE; ATHEROSCLEROSIS; BACK; BUTTOCK; CASE REPORT; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; EAST ASIAN; ECHOCARDIOGRAPHY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FORCEPS DELIVERY; GENE DELETION; GENETIC ANALYSIS; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIGAND BINDING; PERSONAL EXPERIENCE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY; VASCULAR ACCESS; XANTHOMA; ADOLESCENT; AGE; BLOOD; CHILD; COMBINATION DRUG THERAPY; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; HEREDITY; HYPERLIPOPROTEINEMIA TYPE II; MALE; MUTATION; PEDIGREE; PRESCHOOL CHILD; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; BLOOD COMPONENT REMOVAL; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, LDL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MUTATION; PEDIGREE; PHENOTYPE; RECEPTORS, LDL; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928898081     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2015.02.002     Document Type: Article

References (15)

1. Kusters D.M., Huijgen R., Defesche J.C., et al. Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes. Neth Heart J 2011, 19:175-182.
2. Walji S., Neuwirth C., Thompson G.R. Lipoprotein apheresis for the treatment of familial hypercholesterolaemia. Clin Lipidol 2013, 8:573-586.
3. Goldstein J.L., Brown M.S. The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin North Am 1982, 66:335-362.
4. Webb J.C., Sun X.M., McCarthy S.M., et al. Characterisation of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolaemia and frequency of these mutations in FH patients in the UK. J Lipid Res 1996, 37:368-381.
5. Gautschi M., Pavlovic M., Nuoffer J.M. Fatal myocardial infarction at 4.5 years in a case of homozygous familial hypercholesterolaemia. JIMD Rep 2012, 2:45-50.
6. Keller C. LDL-Apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience. Atheroscler Suppl 2009, 10:21-26.
7. Mabuchi H., Nohara A., Noguchi T., et al. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis 2011, 214:404-407.
8. Graesdal A., Bogsrud M.P., Holven K.B., et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol 2012, 6:331-339.
9. Raal F.J., Pilcher G.J., Panz V.R., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124:2202-2207.
10. Gagné C., Gaudet D., Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469-2475. Ezetimibe Study Group.
11. Thompson G.R. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198:247-255. HEART-UK LDL Apheresis Working Group.
12. Thompson G.R., Barbir M., Davies D., et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208:317-321.
13. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478-3490a.
14. Cuchel M., Meagher E.A., du Toit Theron H., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
15. Stein E.A., Honarpour N., Wasserman S.M., Xu F., Scott R., Raal F.J. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013, 128:2113-2120.